Auranofin | 2219

An anti-arthritic drug that inhibits various leukocyte activation pathways at multiple sites. Inhibits release of inflammatory mediators from human basophils, pulmonary mast cells and macrophages. Also inhibits human neutrophil 5-lipoxygenase. Inhibits IκB kinase (IKK) by modifying Cys179 of the IKKß subunit. Efficient inducer of mitochondrial membrane permeability transition via the inhibition of mitochondrial thioredoxin reductase (TrxR).

Auranofin is an anti-arthritic drug that inhibits various leukocyte activation pathways at multiple sites. Inhibits release of inflammatory mediators from human basophils, pulmonary mast cells and macrophages. Inhibits IκB kinase (IKK) by modifying Cys179 of the IKKß subunit. Efficient inducer of mitochondrial membrane permeability transition via the inhibition of mitochondrial thioredoxin reductase (TrxR).

2219 | Auranofin DataSheet

Alternate Name/Synonyms: 1-Thio-β-D-glucopyranosatotriethylphosphine gold-2,3,4,6-tetraacetate; SKF39162

Appearance: White to off-white solid

Formulation: N/A

CAS Number: 34031-32-8

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₀H₃₄AuO₉PS

Molecular Weight: 678.48

Cell-Permeable?: Yes

Purity: ≥98% by NMR

Solubilities: DMSO (100 mM) or Ethanol (50 mM)

Handling: Protect from light and moisture

Country of Origin: USA

Tag Line: Leukocyte activation pathways inhibitor

MDL Number: MFCD00080759

PubChem CID: 24199313

SMILES: CCP(CC)CC.CC(=O)OCC1C(C(C(C(O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.[Au+]

InChi: InChI=1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1

InChi Key: AUJRCFUBUPVWSZ-UHFFFAOYSA-M